BRAIN AF: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic stroke and Neurocognitive Impairment in Atrial Fibrillation
Summary
The BRAIN-AF study is attempting to figure out the best way to treat patients with Atrial Fibrillation and a low risk of having a stroke.
We believe that blood thinners could decrease the rate of stroke and decline in thinking functions, even in people who are not currently recommended to receive them.
Patients in this study will be randomly assigned to receive either a blood thinning medication called rivaroxiban or a placebo (sugar pill) and monitored for things like memory and thinking skills for 6 years.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 30 to 62
Inclusion criteria:
-30-62 years old
-Diagnosed with Atrial Fibrillation
-Low stroke risk: No High blood pressure, diabetes or previous stoke
Exclusion criteria:
-Known dementia
-History of bleeding ulcers
-Surgery in the past month or planned
-Cancer, kidney disease or anemia
-Pregnancy
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Jennifer McKeage R.N. 403-210-6047 jmckeage@ucalgary.ca
Principal investigator:
Stephen Wilton
Clinical trial:
Yes
REB-ID:
REB16-0312